Head-to-head
Semaglutide vs Tesamorelin
A field-by-field comparison of Semaglutide and Tesamorelin drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — metabolic and growth hormone — so this page focuses on what each one actually does rather than which is "better".
Semaglutide vs Tesamorelin: editorial summary
Semaglutide and tesamorelin are both metabolic peptides, but their biological targets and approved uses are very different. Semaglutide is a GLP-1 receptor agonist with broad clinical evidence for diabetes and weight management. Tesamorelin is a GHRH analogue with an approved indication specifically involving excess visceral abdominal fat in people with HIV-associated lipodystrophy.
Key considerations
- Semaglutide primarily acts through the GLP-1 pathway, affecting appetite, glucose-dependent insulin secretion and gastric emptying. Tesamorelin increases endogenous GH and downstream IGF-1 through the GHRH receptor.
- Their regulatory histories are therefore quite different. Both have approved medical uses, but those approvals apply to different conditions and populations. A comparison based purely on "fat loss" can obscure that distinction.
Semaglutide characteristics
- Semaglutide is a long-acting GLP-1 analogue with Strong evidence and approximately a seven-day half-life.
Tesamorelin characteristics
- Tesamorelin is a stabilised GHRH analogue with Strong evidence. PeptideIndex identifies it as FDA-approved for a specific indication rather than as a general weight-loss medicine.
Semaglutide vs Tesamorelin at a glance
| Attribute | Semaglutide | Tesamorelin |
|---|---|---|
| Category | Metabolic | Growth hormone |
| Evidence grade | Strong | Strong |
| Also known as | Ozempic, Wegovy | Egrifta, TH9507 |
| Chain | GLP-1 analogue, 94% homology to human GLP-1 | 44 amino acid stabilised GHRH analogue |
| Mechanism | Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. | A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1. |
| Reported benefits | ~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise | Clinically demonstrated visceral adipose tissue reduction (~15–18%) · Improved triglycerides in trial populations · Preliminary evidence for cognitive benefit in older adults |
| Reported side effects | Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history | Joint pain and swelling · Injection-site erythema · Insulin resistance · Peripheral oedema |
| Half-life | About 7 days | 26–38 minutes |
| Administration | Once-weekly subcutaneous injection (oral tablet also approved) | Daily subcutaneous injection, abdomen |
| Dosing overview | Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks | Approved label dose is 2 mg once daily |
| Storage | Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label | Refrigerated; reconstitute immediately before use per label |
| Legal status | FDA-approved and prescription-only. | FDA-approved for a specific indication; other uses are off-label. |
Key differences between Semaglutide and Tesamorelin
Different categories, different goals
Semaglutide is indexed under metabolic, while Tesamorelin sits under growth hormone. They are not substitutes for one another: Semaglutide is described as "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market." and Tesamorelin as "The one GH-axis peptide with full FDA approval, indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy."
Mechanism of action
Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. Tesamorelin: A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1.
Half-life and dosing frequency
Semaglutide is listed at about 7 days; Tesamorelin at 26–38 minutes. That difference is what drives the reported schedules: Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks versus Approved label dose is 2 mg once daily
Route of administration
Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved). Tesamorelin is administered by daily subcutaneous injection, abdomen.
Legal and regulatory status differs
Semaglutide: FDA-approved and prescription-only. Tesamorelin: FDA-approved for a specific indication; other uses are off-label. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label. Tesamorelin is stored refrigerated; reconstitute immediately before use per label.
What Semaglutide and Tesamorelin have in common
- Evidence grade: both listed as Strong
Each compound in brief
Semaglutide
Metabolic · Strong evidence
A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.
Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping
Tesamorelin
Growth hormone · Strong evidence
The one GH-axis peptide with full FDA approval, indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy.
Considerations: Visceral fat returns after discontinuation · Requires monitoring of fasting glucose and IGF-1 · Expensive relative to other GH secretagogues
Frequently asked questions
Do semaglutide and tesamorelin work in the same way?
No. Semaglutide activates the GLP-1 receptor, while tesamorelin activates the GHRH pathway and increases endogenous GH.
Are both approved medicines?
Yes, but their approved indications differ substantially.
Is tesamorelin simply another GLP-1 medicine?
No. Tesamorelin is a GHRH analogue and has a completely different mechanism from GLP-1 receptor agonists.
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.